文 献1）Bryson HM, Palmer KJ, Langtry HD, Fitton A. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 1993; 45: 85-130.2）Jürgens G, Graudal NA, Kampmann JP. Therapeutic drug monitoring of antiarrhythmic drugs. Clin Pharmacokinet 2003; 42: 647-63.3）Steurer G, Weber H, Schmidinger H, Plass H, Frey B, Pürerfellner H, et al. Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy. Eur Heart J 1991; 12: 526-32.4）Doki K. Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug. Yakugaku Zasshi 2018; 138: 1145-50.5）Bezzina CR, Shimizu W, Yang P, Koopmann TT, Tanck MW, Miyamoto Y, et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation 2006; 113: 338-44.6）Doki K, Homma M, Kuga K, Aonuma K, Kohda Y. SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients. Pharmacogenet Genomics 2013; 23: 349-54.7）Doki K, Homma M, Kuga K, Aonuma K, Kohda Y. CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis. Pharmacogenet Genomics 2012; 22: 777-83.8）Shirayama Y, Doki K, Sekiguchi Y, Aonuma K, Kohda Y, Homma M. Simultaneous determination of serum propafenone and its metabolites using high-プロパフェノンの薬理遺伝学的情報に基づく効果的な治療薬物モニタリングperformance liquid chromatography. Biomed Chromatogr 2018; 32: doi: 10.1002/bmc.4099.9）Axelson JE, Chan GL, Kirsten EB, Mason WD, Lanman RC, Kerr CR. Food increases the bioavailability of propafenone. Br J Clin Pharmacol 1987; 23: 735-41.10）Jazwinska-Tarnawska E, Orzechowska-Juzwenko K, Niewinski P, Rzemislawska Z, Loboz-Grudzien K, Dmochowska-Perz M, et al. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment. Int J Clin Pharmacol Ther 2001; 39: 288-92.11）Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75: 785-91.12）Cai WM, Xu J, Chen B, Zhang FM, Huang YZ, Zhang YD. Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia. Acta Pharmacol Sin 2002; 23: 1040-4.13）Doki K, Shirayama Y, Sekiguchi Y, Aonuma K, Kohda Y, Homma M. Optimal sampling time and clinical implication of the SCN5A promoter haplotype in propafenone therapeutic drug monitoring. Eur J Clin Pharmacol 2018; 74: 1273-9.107
元のページ ../index.html#121